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Background: Congestion is the main reason for hospital admission for acute 
decompensated heart failure (ADHF). A better understanding of the clinical course of 
congestion and factors associated with decongestion are therefore important. We 
studied the clinical course, predictors and prognostic value of congestion in a cohort of 
patients admitted for ADHF by including different indirect markers of congestion 
(residual clinical congestion, Brain natriuretic peptides (BNP) trajectories, 
hemoconcentration or diuretic response). 
Methods and results: We studied the prognostic value of residual clinical congestion 
using an established composite congestion score (CCS) in 1572 ADHF patients. At 
baseline, 1528 (97.2%) patients were significantly congested (CCS≥3), after 7 days of 
hospitalization or discharge (whichever came first), 451 (28.7%) patients were still 
significantly congested (CCS≥3), 751 (47.8%) patients were mildly congested (CCS=1 or 
2) and 370 (23.5%) patients had no signs of residual congestion (CCS=0). The presence 
of significant residual congestion at day 7 or discharge was independently associated 
with increased risk of re-admissions for heart failure by day 60 (HR [95%CI] = 1.88 
[1.39-2.55]) and all-cause mortality by day 180 (HR[95%CI] = 1.54 [1.16-2.04]). Diuretic 
response provided added prognostic value on top of residual congestion and baseline 
predictors for both outcomes, yet gain in prognostic performance was modest.  
Conclusion: Most patients with acute decompensated heart failure still have residual 
congestion 7 days after hospitalization. This factor was associated with higher rates of 
re-hospitalization and death. Decongestion surrogates, such as diuretic response, 
added to residual congestion, are still significant predictors of outcomes, but they do 
not provide meaningful additive prognostic information.  
 3 
KEY WORDS: Heart Failure; Congestion; Diuretic response. 
 4 
Introduction 
Most patients needing hospital admission for decompensated heart failure present 
with signs and symptoms of congestion [1]. Relief of signs and symptoms of congestion 
(i.e. decongestion) is one of the main goals of in-hospital treatment in these patients 
[2,4,5]. 
However, adequate decongestion is often not achieved during hospital admission. In a 
recent post-hoc analysis of DOSE-AHF and CARESS-HF [6,7], only half of the patients 
were free from signs of congestion at discharge, and these patients had lower rates of 
death and re-hospitalization at day 60. Similarly, using a composite congestion score 
(Supplementary table 1) that comprised orthopnea, jugular venous distension (JVD) 
and peripheral edema, Ambrosy et al [7] showed that a significant proportion of 
patients still had residual congestion by day 7 or discharge, and these patients had 
increased risks of readmission and mortality. 
Improved clinical assessment of residual congestion is therefore paramount, and a 
better understanding of the clinical course of congestion and factors associated with 
decongestion could play an important role towards the implementation of targeted 
strategies that can reduce residual congestion and, potentially, improve outcomes [8]. 
Nonetheless, assessment of decongestion based strictly on clinical findings may be 
non-sensitive. It has been shown that the change in BNP concentrations [9] and 
hematocrit during hospitalization [10], as surrogates markers of congestion, add 
significant prognostic information related with residual congestion.  In addition, the 
metrics of diuretic response seems to be crucial in achieving a safe decongestion  
[8,11-13,28]. The combination of objective measures of decongestion on top of clinical 
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assessment may help to detect lesser degrees of congestion and lead to a more 
accurate and safe treatment and follow-up.  
We therefore aimed to: (i) characterize the clinical course of congestion (ii)  evaluate 
predictors of residual congestion by day 7 (iii) assess the prognostic value of residual 
congestion by day 7 and (iiii) evaluate the prognostic value of decongestion markers 
along with clinical findings of residual congestion in patients hospitalized for 
decompensated heart failure.  
Methods 
Study population and procedures 
Data from PROTECT (Placebo-controlled Randomized Study of the Selective A1 
Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute 
Decompensated Heart Failure and Volume Overload to assess Treatment Effect on 
congestion and Renal function) were utilized in this study [14,15]. The PROTECT trial 
was designed to study rolofylline, an adenosine A1-receptor antagonist as a new 
treatment for ADHF capable of improving renal function and relieving dyspnea. Main 
inclusion criteria were persistent dyspnea at rest, impaired renal function, high titers 
of natriuretic peptides, ongoing intravenous loop diuretic therapy and enrollment 
within 24 hours after admission [11,14]. Other inclusion and exclusion criteria have 
been previously described [14]. The main findings were neutral with respect to the 
primary outcome [11]. 
Clinical assessment of symptoms and signs, including orthopnea, rales, edemas, JVD, 
dyspnea and body weight was performed daily by clinicians until day 7 or discharge (if 
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earlier), and day 14. Diuretic response was calculated as ∆ body weight in the first 72 
hours/40mg i.v. furosemide or equivalent [28]. Standard laboratory parameters were 
measured in a central laboratory (ICON laboratories, Farmingdale, New York).  
Composite congestion score 
A composite congestion score was calculated for individual patients at baseline and 
on days 2, 3, 4, 7 and 14 using a modified algorithm from the one described by 
Ambrosy et al [7]. The composite congestion score was calculated by summing the 
individual scores for orthopnea (0 to 3), peripheral edema (0 to 3) and JVD (0 to 2). In 
contrast to the previously published composite congestion score [7], the maximum 
possible score was 8 points in the current study as the coding of JVD was slightly 
different in the PROTECT trial (Supplementary table 2).  
Surrogate markers of decongestion 
We, thereafter, included several objective measurements of decongestion on top of 
the aforementioned clinical findings. 
Changes in concentration of BNP was defined as (BNP day 7 or discharge-BNP day 1), 
To calculate percentage change in brain natriuretic peptide (BNP) till day 7 or day 14 
from baseline, we used non-commercial plasma BNP measured using a single 
molecule counting technology with the Erenna® Immunosay System on a microtitre 
plate assay format from frozen plasma samples (Singulex Inc., Alameda, CA, USA). 
BNP at baseline was available in 1,585 patients. BNP at day 7 was available in 1,442 
patients. 1,248 patients had complete BNP data available on both time points. 
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Hemoconcentration was defined as the change in hemoglobin at discharge or day 7 
and diuretic response was calculated as ∆ body weight in the first 72 hours/40mg i.v. 
furosemide or equivalent [28]. Also, change in estimated plasma volume (delta ePVS) 
was evaluated. [29] 
Study outcomes 
Two time-to-event outcomes, heart failure re-hospitalization by day 60 and all-cause 
mortality by day 180 were assessed. Follow-up for these analyses started at day 7, as 
the follow-up started before the end of the index hospitalization, we did not report 
death during hospitalization as these were included in the all-cause mortality by day 
180 endpoint.  All re-hospitalizations after index hospitalization and all causes of death 
through day 60 had been adjudicated by an independent clinical events committee. 
Statistical analysis 
Baseline clinical characteristics and standard laboratory parameters were 
summarized and compared in three groups based on composite congestion score on 
day 7 (0= no congestion, 1-2= mild congestion and 3-8= significant congestion). 
Continuous variables were summarized as mean ± SD or median (interquartile range) 
as appropriate. ANOVA (for normally distributed variables) or Kruskall-Wallis (for non-
normally distributed variables) tests were used for group comparisons. Categorical 
variables were compared among groups with the chi-square test. No imputations were 
performed for missing values. 
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The clinical course of congestion within the first 14 days of the index hospitalization 
was graphically assessed by plotting the proportion of patients within each of the 
three groups over multiple time points; baseline and 2, 3, 4, 7 and 14.  
A multivariable explanatory logistic regression model was developed to identify 
factors independently associated with the presence of significant residual congestion 
by day 7. Candidate predictors were first selected based on a p-value<20%, next 
utilizing an Akaike information criterion (AIC) based backward selection procedure. 
An internal bootstrap with 1000 replicates of the selected models was performed, 
testing stability of these models. List of candidate variables considered for this model 
are included in supplementary material. Before the implementation of the stepwise 
selection procedure, linearity of association between baseline parameters and residual 
congestion by day 7 was evaluated using fractional polynomials and appropriate 
transformations were performed as necessary.   
Unadjusted associations between the presence of significant residual congestion by 
day 7 and clinical outcomes were assessed using univariable cause-specific Cox 
proportional hazards models. The assumption of proportional hazards was checked 
and satisfied.  Adjusted associations were further evaluated with multivariable cause-
specific Cox proportional hazards models that included previously identified predictors 
for the 180-day all-cause mortality outcome [15]. These encompassed baseline 
variables including age, peripheral edema, past heart failure hospitalization, systolic 
blood pressure (SBP), serum creatinine, blood urea nitrogen (BUN), albumin, sodium. 
For the 60-day heart failure rehospitalization outcome, a baseline model 
encompassing history of diabetes mellitus, percutaneous intervention (PCI), COPD, 
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coronary artery bypass graft (CABG), heart failure hospitalization within the past year, 
albumin, BUN, hematocrite, sodium, edema and JVD was developed after 
implementation of a AIC-based backward selection procedure on a Cox regression 
model that included candidate predictors associated with outcome at a significance 
level of 20%. This procedure was performed in multiple bootstrap samples using R 
package bootStepAIC.  
Unadjusted and adjusted associations between the other decongestion markers (i.e. 
change in BNP from baseline to day 7, diuretic response and hemoconcentration) were 
assessed in univariable and multivariable cause-specific proportional hazards models. 
Adjusted associations were evaluated in multivariable models that include the 
previously defined baseline predictors of each outcome and residual clinical 
congestion at day 7. Added prognostic value was quantified with the gain in the 
Harrell’s C-index.  
Estimates are presented with 95% confidence intervals. P-value<0.05 was considered 
statistically significant. Statistical analyses were performed with SPSS version 22.0 (IBM 
Corp., Armonk, NY) and R: Language and Environment for Statistical Computing, 
version 3.0.2. (R Foundation for Statistical Computing, Vienna, Austria). 
Results 
Baseline characteristics 
Of the 2033 patients included in PROTECT, 1572 patients had complete available 
assessment of orthopnea, JVD and peripheral edema at day 7. Patients with missing 
values were comparable to patients with available measurements (See Supplementary 
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tables 3 & 4). The majority of patients were male (67.1%), with a mean age of 70.1 ± 
11.5 years, and had a previous history of heart failure hospitalizations (94.8%). 
hypertension (79.4%), ischemic heart disease (69.7%), hyperlipidemia (51.9%), 
atrial/flutter fibrillation (54.6%) and diabetes (45.4%). (Table 1).  
Evolution of composite congestion score during 14 days of baseline 
assessment 
Nearly all patients included in the study (97.2%) had moderate to severe congestion at 
baseline as assessed by the composite clinical congestion score. At baseline, the 
median [IQR] composite congestion score was 5 [4-6]. A significant reduction in the 
composite congestion score was observed during the next 7 days after baseline 
assessment (Supplementary figure 1). The median [IQR] composite congestion score 
declined from 5 to 2 [1-3] by day 7. However, 29% of patients still had significant 
residual congestion by day 7 or discharge while more than 75% had a composite 
congestion score > 0. The composite congestion score further declined to a median 
[IQR] value of 1 [0-3] by day 14 although 25% of evaluated patients still had significant 
residual congestion (Supplementary figure 1). 
Factors associated with the presence of significant congestion by day 7 
Table 1 shows baseline characteristics of patients with no, moderate, significant clinical 
congestion at day 7. Patients with significant residual congestion by day 7 had higher 
BMI [29.5 [26.1-34.5);p=<0.001], lower systolic and diastolic blood pressure [120 
(109.0-138.0);p=0.011]-[71 (63.0-80.0); p=0.017] and showed a higher prevalence of 
hyperlipidemia (59.3%; p=<0.001), diabetes (54.3%; p=<0.001), ischemic coronary 
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disease (24.4%; p=<0.001) and CABG (27.5%; p=<0.001). Also, patients with significant 
clinical congestion at day 7 had higher BNP levels at day 7 and showed significantly less 
hemoconcentration (supplementary table 7).  
Higher baseline BUN levels, poorer diuretic response, lower ALT and total cholesterol, 
higher BMI and BNP and a history of pacemaker implantation were found to be 
independent predictors of the presence of significant residual clinical congestion by 
day 7 (Table 2) This model had an AUC of 0.80. 
Residual clinical congestion and outcomes 
Among the 1572 patients who had composite congestion score assessment by day 7, 
15.8% (N=249) died by day 180 and 13.7% (N=215) were re-hospitalized for heart 
failure at least once by day 60. Using Fine-Gray analysis we did not find a significant 
effect of competing risk (P-0.11, supplementary figure 2).  
As presented in the Kaplan-Meier plots in Figures 1 & 2, the rates of both all-cause 
mortality by day 180 and heart failure re-hospitalization by day 60 increased 
significantly with increasing severity of residual clinical congestion by day 7. The risk of 
all-cause mortality by day 180 more than doubled in patients with significant 
congestion by day 7 compared to those with no or mild congestion, (Hazard Ratio (HR) 
2.13, 95% CI [1.66-2.73]). The risk of heart failure re-hospitalization by day 60 was also 
significantly greater in patients with significant residual congestion by day 7, (HR 1.88, 
95% CI [1.43-2.46]). The risk associated with significant residual congestion by day 7 
remained significantly increased even after adjustment for the baseline risk prediction 
models (Supplementary table 5).  
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Added prognostic value of other decongestion markers on top of residual 
clinical congestion 
Diuretic response was independently predictive of both HF-rehospitalization by day 60 
and all-cause mortality by day 180 on top of residual clinical congestion and the 
baseline models. However, the gain the Harrell’s C-index was modest for both 
outcomes (Supplementary Table 6).  
On the other hand, hemocentration and also delta estimated plasma volume was 
strongly associated with all-cause mortality by day 180, yet the gain in the Harrell’s 
C-index was modest. (Supplementary Table 6) 
Discussion 
In the present study, we demonstrate that one third of patients were still significantly 
congested at day 7. Residual congestion was associated with increased risks of death 
and heart failure re-hospitalization.  
Our findings support previous results reported from the DOSE, CARRESS-HF and 
EVEREST trials, showing that residual congestion at day 7 or discharge is present in 
most patients admitted for ADHF and that residual congestion was related to poor 
clinical outcome [6,7,16,17]. In addition, consistent with previous studies, we 
identified higher BMI, BUN and the presence of comorbidities (e.g. diabetes) as 
important predictors of residual congestion [6]. Besides validating the existing body of 
evidence on clinically assessed residual congestion in ADHF patients, the current study 
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provides novel information. The clinical course of congestion was more extensively 
characterized during hospitalization as physician assessment of clinical congestion was 
performed daily through day 4 in most patients included in the PROTECT trial. 
Interestingly, a significant decline in the composite clinical congestion score was 
already observed by day 4 as more than half of patients with significant congestion 
during baseline assessment regressed to no/mild congestion by day 4. However, 
regardless of the rapid improvement of congestion by day 4, no differences were 
found in length of hospital stay when patients were classified by their day 7 congestion 
score. This indicates that the decision to discharge patients is less likely to be driven by 
residual clinical congestion status. 
Finally, residual congestion was also linked to heart failure treatment. Patients with 
some grade of residual congestion at day 7 or discharge, were being treated in a 
lower proportion with ACEi/ARBs (p=0.017). Probably some factors as hypotension 
or a poorer renal function can explain this situation, those patients being “cold and 
wet” at physical examination have worse prognosis, indicating that they have and 
advanced heart failure situation and are severely congested. 
Predictors of residual congestion 
The strongest independent predictors of residual congestion were higher BUN on 
admission, a more severe clinical congestion at baseline and a poorer diuretic 
response. 
Diuretic response reflects the effectiveness of loop diuretics to force diuresis and 
natriuresis [12,18,19]. A poorer diuretic response has been associated with more 
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advanced heart failure, residual congestion and renal impairment, being predictive for 
mortality and heart failure re-hospitalization [11,13,18-21].  
Blood urea nitrogen (BUN) is directly linked with diuretic response. Firstly, higher BUN 
is a marker of renal dysfunction, and renal dysfunction is a predictor of a poor diuretic 
response. Secondly, BUN is a marker of neurohormonal activation, which increases 
renal water and sodium retention to recover cardiac output when myocardial injury is 
developed [23-25]. The chronic neurohormonal activation leads to interstitial volume 
expansion and increase of central venous pressure, which in essence, is the definition 
of congestion [24]. Thirdly, BUN might directly have a negative effect in tubular 
response, since it is bound to the organic anion transporter [12]. Diuretic response and 
BUN therefore overlap, but were also independent predictors of residual congestion at 
day 7 or discharge.   
In the multivariable analysis, body mass index (BMI), was also selected as an 
independent predictor for residual congestion, but this result must be interpreted with 
caution. Higher weight might simply reflect more congestion [24-26].  
Lower total cholesterol levels were also independently associated with residual clinical 
congestion, possibly since more congested patients were more often patients with 
ischemic heart disease, and they might have a tighter control of total cholesterol 





Predicting HF-rehospitalizations by using decongestion markers 
We have found a strong association between clinical residual congestion and clinical 
outcome. The increased risk of hospital readmission in patients with more residual 
congestion is of particular interest, since it is more difficult to predict hospital 
readmission than death, and this particular association suggests that congestion 
should be studied as a marker of intensified decongestion [27] , potentially leading to a 
reduction of early post-discharge hospital readmission.  
Different models based on congestion signs and symptoms have been applied before 
with good results [6-7]. However, when using these models to assess congestion 
during an ADHF admission to predict HF-rehospitalizations, our results are in line with 
those found in DOSE-HF and CARESS-HF trials [7], confirming that there is a 
considerable group of patients who still have a high grade of residual congestion at 
discharge, probably because we adjust HF-treatment using an imprecise tool such as 
physical examination, which depends on the skills and experience of the physician. 
For that purpose, several objective congestion markers as hemoconcentration, 
reduction in BNP [9], and diuretic response [12,18-19] have been included to assess 
whether they improved prognostic capacity of clinical congestion findings alone. 
Although all of them were significantly associated with residual congestion, and thus 
with prognosis, they actually did not provide relevant improvement in prognostic 
performance on top of baseline predictors and residual congestion for both heart 
failure re-admission and mortality outcomes. These results underline the importance 
of a thorough physical examination before discharge for an episode of ADHF.  
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Our study suggests that strategies to improve decongestion and to discharge patients 
with less signs and symptoms of congestion might be a therapeutic target. However, 
prospective interventional studies are needed to establish whether decongestion 
might be a therapeutic target in patient with a hospital admission for heart failure.  
Limitations  
This study is a post-hoc analysis of a randomized clinical trial (PROTECT), with all 
limitations as such. For calculating the composite congestion score an important group 
of patients were lost during the analysis (n=461). Besides, data on signs and 
symptoms of congestion were not collected per protocol at discharge, which could 
have added additional value to the analysis. 
 In addition, the analysis of added prognostic value of decongestion surrogates on top 
of residual clinical congestion was performed in different subsets of patients for each 
decongestion surrogate depending on the availability of data for each of the 
surrogates; performance of the baseline model + residual clinical congestion was 
slightly different across the subsets which might explain some of the discrepancies 
between the C-index and gain in C-index across the estimates for the different 
decongestion parameters (Suplemmentary table 5).  
Conclusions 
Residual congestion at day 7 or discharge was frequently found in patients with a 
hospital admission for ADHF. The strongest predictors of the presence of significant 
residual congestion by day 7 were more congestion at baseline, a poorer diuretic 
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response and increased BUN. Patients who had significant congestion by day 7 had 
worse outcomes in terms of mortality and re-hospitalization for ADHF.  
Surrogate markers of congestion as diuretic response had limited additive value to 
better predict HF-outcomes. 
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Table 1: Baseline characteristics by CCS at Day 7 
 NOT CONGESTION 
(CCS=0) 
MILD CONGESTION 




Total [n(%)] 370 (23.5) 751 (47.8) 451 (28.7)  
Age (years) 69.6 ± 11.9 70.33 ± 11.1 70.8 ± 11.2 0.362 
Male[n(%)] 239 (64.6) 503 (67.0) 300 (66.5) 0.724 
BMI (Kgs/m2) 27.0 (23.7-30.4) 27.1 (24.2-31.1) 29.5 (26.1-34.5) <0.001 
Systolic BP at screening  (mmHg) 126.5 (110.0-140.0) 124.0 (110.0-140.0) 120.0 (109.0-138.0) 0.011 
Diastolic BP at screening  
(mmHg) 
75.0 (70.0-80.0) 75.0 (68.0-80.0) 71.0 (63.0-80.0) 0.017 
Heart rate at screening  (b.p.m) 80.0 (70.0-90.0) 78.0 (69.0-90.0) 78.0 (69.0-89.0) 0.121 
NYHA [n(%)]    0.002 
• I/II 82 (23.6) 104 (14.6) 70 (16.1)  
• III 155 (44.5) 369 (51.8) 239 (54.8)  
• IV 111 (31.9) 240 (33.7) 127 (29.1)  
JVD>10cm [n(%)] 111 (30.2) 288 (38.9) 221 (50.6) <0.001 
Rales more than 2/3 [n(%)] 34 (9.2) 62 (8.3) 60 (13.3) 0.001 
Edema +3 [n(%)] 58 (15.7) 161 (21.4) 206 (45.7) <0.001 
Orthopnea >30 degrees [n(%)] 122 (33.2) 291 (39.4) 251 (56.5) <0.001 
Baseline Composite congestion 
score 
5 (3-6) 5 (4-6) 6 (5-7) <0.001 
Rolofylline treatment 248 (67.0) 505 (47.9) 302 (67.0) 0.994 
HF treatment [n(%)]     
• ACE or ARB 289 (78.1) 581 (77.4) 319 (70.7) 0.016 
• B-blockers 274 (74.1) 580 (77.2) 363 (80.5) 0.089 
• MRA 157 (42.4) 331 (44.1) 190 (42.1) 0.767 
• Digoxin 115 (31.1) 205(27.3) 138 (30.6) 0.305 
History of: [n(%)]     
• Congestive HF 348 (94.1) 713 (94.9) 437 (96.9) 0.132 
• Hypertension 293 (79.2) 591 (78.7) 373 (82.7) 0,222 
• Hyperlipidemia 162 (43.8) 391 (52.1) 267 (59.3) <0.001 
• Peripheral Vascular 
disease 
39 (10.6) 72 (9.6) 52 (11.6) 0.549 
• Asthma/Bronchitis/COP
D 
72 (19.5) 142 (18.9) 100 (22.3) 0.334 
• Diabetes Mellitus 144 (38.9) 330 (44.0) 245 (54.3) <0.001 
• Angina 93 (25.1) 173 (23,0) 79 (17.6) 0,020 
• ICD 40 (10.8) 104 (13.8) 110 (24.4) <0.001 
• IHD 234 (63.2) 547 (73.0) 307 (68.2) 0.003 
• MI 169 (45.7) 391 (52.3) 213 (47.3) 0.071 
• CABG 46 (12.5) 174 (23.4) 123 (27.5) <0.001 
• PCI 81 (22.1) 195 (26.2) 129 (28.8) 0.096 
• Atrial Fibrillation/Flutter 185 (50.3) 388 (52.1) 272 (60.9) 0.003 
• Pacemaker 32 (8.6) 88 (11.7) 63 (14.1) 0.056 
• Biventricular Pacing 21 (5.7) 70 (9.3) 75 (16.6) <0.001 
Values are expressed as mean ± SD or Median (25th,75th). BMI, Body Mass Index; NYHA, New York Heart Assosiation; 
JVD, jugular venous distension; HF, Heart Failure; ACE, Angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II 
receptor blocker; MRA, mineralocorticoid receptor antagonist; COPD, Chronic obstructive pulmonary disease; ICD, 
implantable cardioverter-defibrillator; ICP, Internal Cardiac Desfibrillator;; IHD, Ischemic Heart Disease; MI, myocardial 













 NOT CONGESTION 
(CCS=0) 
MILD CONGESTION 





LVEF (%) 32.0 (23.5-41.5) 30.0 (22.5-40.0) 27.7 (20.0-40.0) 0.044 
BUN (mg/dL) 26.0 (21.0-36.0) 28.0 (21.0-39.0) 35.0 (24.0-48.5) <0.001 
Creatinine  (mg/dL) 1.3 (1.10-1.60) 1.4 (1.1-1.7) 1.5 (1.2-1.9) <0.001 
eGFR  
(mL/min/1.73m2) 
49.5 (38.1-66.6) 48.4 (36.0-64.0) 42.6 (32.4-58.4) <0.001 
Hematocrit (%) 41.0 (37.4-44.8) 40.0 (35.9-44.2) 38.5 (34.9-42.9) <0.001 
Hemoglobin  (g/dL) 13.1 (11.8-14.4) 12.6 (11.3-13.9) 12.0 (10.9-13.5) <0.001 
Glucose   121.0 (98.5-158.0) 127.0 (103.0-164.0) 128.0 (103.0-168.0) 0.048 
Albumin   3.9 (3.7-4.2) 3.9 (3.6-4.1) 3.7 (3.5-4.1) <0.001 
Sodium (mmol/L) 141.0 (138.0-143.0) 140.0 (137.0-142.0) 139.0 (136.0-142.0) <0.001 
Potassium  
(mmol/L) 
4.2 (3.9-4.6) 4.2 (3.8-4.6) 4.2 (3.8-4.6) 0.514 
Chloride  (mmol/L) 102.0 (100.0-105.0) 101.0 (98.0-104.0) 100.0 (97.0-100.4) <0.001 
Bicarbonate  
(mmol/L) 
24.0 (21.0-26.0) 24.0 (21.0-26.0) 24.0 (21.0-27.0) 0.540 
Cholesterol  
 
152.0 (125.5-182.0) 143.0 (117.0-175.2) 127.0 (104.0-160.0) <0.001 
Triglycerides  
 
90.0 (66.0-137.0) 91.0 (66.0-125.0) 82.0 (64.0-112.0) 0.013 
BNP  (ng/L) 479.0 (264.6-799.6) 425.46 (258.7-771.3) 502.4 (263.4-915.6) 0.046 
Total dose of IV 
loop diuretic until 
day 7 or discharge 
(mg of furosemide)  
209 (100-365) 240 (120-491) 400 (200-920) <0.001 
Study day of 
discharge  (n) 
8 (7-14) 8 (5-14) 9 (5-16) 0.108 
All values are expressed as Median (25th,75th).  LVEF, Left Ventricular Ejection Fraction; BUN, Blood urea nitrogen; eGFR, Estimated 
Glomerular Filtration rate calculated by the simplified modification of diet in renal disease equation,; BNP, Brain Natriuretic Peptide;  
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Table 2: Factors associated with the presence of significant residual congestion by day 7; a 
multivariable logistic regression model.  
 
Variable Z-Score OR [95% CI] P-value 




69.7 1.70 [1.50-1.92] <0.001 
 
 
BUN  22.3 1.48[1.25-1.74] <0.001 
Diuretic response 
 
17.9 1.65[1.31-2.09] <0.001 
BMI 
 
17.3 1.45[1.22-1.73] <0.001 
 
Total Cholesterol  
 
9.7 0.75[0.63-0.90] 0.002 
Ln(ALT) 7.1 0.79[0.67-0.94] 0.008 
History of Pacemaker 
 
6.8 1.89[1.17-3.04] 0.009 
BNP 6.5 1.23[1.05-1.44] 0.010 
Factors have been ordered by Z-Score  
AUC for this multivariable model is 0.80                                                                                                                                                          
CCS, Composite Congestion Score; BUN, Blood Urea Nitrogen; BMI, Body Mass Index; BNP, Brain 
Natriuretic Peptide. For continuous variables ORs should be interpreted per SD. 
 
 
 
 
 
 
